Send to

Choose Destination
Neurobiol Aging. 2017 Jan;49:215.e1-215.e8. doi: 10.1016/j.neurobiolaging.2016.09.008. Epub 2016 Sep 23.

Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array.

Author information

School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK. Electronic address:
School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.
Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK.


We have screened sporadic early-onset Alzheimer's disease (sEOAD, n = 408) samples using the NeuroX array for known causative and predicted pathogenic variants in 16 genes linked to familial forms of neurodegeneration. We found 2 sEOAD individuals harboring a known causative variant in PARK2 known to cause early-onset Parkinson's disease; p.T240M (n = 1) and p.Q34fs delAG (n = 1). In addition, we identified 3 sEOAD individuals harboring a predicted pathogenic variant in MAPT (p.A469T), which has previously been associated with AD. It is currently unknown if these variants affect susceptibility to sEOAD, further studies would be needed to establish this. This work highlights the need to screen sEOAD individuals for variants that are more classically attributed to other forms of neurodegeneration.


Alzheimer's disease; Early-onset; NeuroX; Parkinson's disease; Screening; Sporadic

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center